Comparative Pharmacology
Head-to-head clinical analysis: DORAL versus MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORAL versus MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE.
DORAL vs MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization.
15-30 mg orally at bedtime, maximum 60 mg/day.
0.5-2 mg slow IV over 2 minutes, may repeat q2-3min; typical total dose 2.5-5 mg. IM: 0.07-0.08 mg/kg (usual 5 mg).
None Documented
None Documented
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life is 1.8-2.5 hours in healthy adults. In critically ill patients or those with hepatic impairment, half-life may extend to 2-6 hours. Obesity may prolong half-life due to increased volume of distribution.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Primarily renal elimination of hydroxylated metabolites (midazolam 1-hydroxymidazolam and 4-hydroxymidazolam) as glucuronide conjugates. Only 0.03% of unchanged drug is excreted renally. Fecal excretion accounts for <2%.
Category C
Category D/X
Benzodiazepine
Benzodiazepine